drugset
drugset / Trial / NCT02987400

Combination of Obinutuzumab and Venetoclax in Relapsed or Refractory DLBCL

NCT02987400 ↗

Phase 2 Completed 22 enrolled Study Group of Medical Tumour Therapy (AGMT) Roche Pharma AG · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the clinical activity and tolerability of a combination of obinutuzumab plus venetoclax in patients with relapsed or refractory diffuse large B-cell lymphoma.

Timeline

Start
2017-01-04
Primary completion
2021-10-19
Completion
2021-10-19

Drugs

EvaluationDrugModalityDoseRoute
Subject Obinutuzumab Monoclonal antibody 1000 mg Intravenous
Subject Venetoclax Small molecule 800 mg Oral

Indications

diffuse large B-cell lymphoma